Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Sanjay Nayak sold 1,832 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $9.02, for a total transaction of $16,524.64. Following the sale, the insider now directly owns 176,194 shares of the company’s stock, valued at approximately $1,589,269.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Ocular Therapeutix Stock Performance
NASDAQ:OCUL opened at $9.04 on Wednesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 16.64 and a quick ratio of 16.55. The firm has a market capitalization of $1.40 billion, a price-to-earnings ratio of -6.70 and a beta of 1.30. The company’s 50-day moving average is $7.71 and its two-hundred day moving average is $7.43. Ocular Therapeutix, Inc. has a 1-year low of $2.00 and a 1-year high of $11.31.
Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.04). The firm had revenue of $16.40 million during the quarter, compared to analyst estimates of $15.85 million. Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The business’s revenue for the quarter was up 7.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.27) earnings per share. Analysts forecast that Ocular Therapeutix, Inc. will post -1.02 EPS for the current year.
Hedge Funds Weigh In On Ocular Therapeutix
Wall Street Analyst Weigh In
A number of analysts have recently commented on OCUL shares. TD Cowen cut shares of Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 21st. JMP Securities cut their target price on shares of Ocular Therapeutix from $24.00 to $22.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 8th. HC Wainwright restated a “buy” rating and set a $14.00 price target on shares of Ocular Therapeutix in a research report on Thursday, August 1st. Robert W. Baird lowered their price target on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Piper Sandler restated an “overweight” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $15.67.
Check Out Our Latest Report on Ocular Therapeutix
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
See Also
- Five stocks we like better than Ocular Therapeutix
- How Technical Indicators Can Help You Find Oversold Stocks
- Akamai: AI Tailwinds Drive Edge Computing and Security Growth
- What Does a Stock Split Mean?
- DoorDash Stock Sprints Higher on EPS Beat and Raised Guidance
- Investing in Construction Stocks
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.